The Wall Street Transcript
The Wall Street Transcript - In-Depth Interviews for Investors

IPOs

February 12, 2016

Buy ($175)

Companies covered: ServisFirst Bancshares, Inc. (NASDAQ:SFBS), Aldeyra Therapeutics, Inc. (NASDAQ:ALDX), Radius Health, Inc. (NASDAQ:RDUS), Superior Drilling Products, Inc. (NYSEAMERICAN:SDPI), K2M Group Holdings, Inc. (NASDAQ:KTWO), Franklin Financial Network Inc. (NYSE:FSB)

Interview with the EVP, CFO, Treasurer and Secretary: ServisFirst Bancshares, Inc. (NASDAQ:SFBS)
William M. Foshee
Interview with the CEO, President and Director: Aldeyra Therapeutics Inc. (NASDAQ:ALDX)
Todd C. Brady
Interview with the President and CEO: Radius Health Inc. (NASDAQ:RDUS)
Robert Ward
Interview with the Chairman and CEO: Superior Drilling Products, Inc. (NYSEMKT:SDPI)
Troy Meier
Interview with the President, CEO and Co-Founder: K2M Group Holdings Inc. (NASDAQ:KTWO)
Eric Major
Interview with the Chairman and CEO: Franklin Financial Network Inc. (NYSE:FSB)
Richard E. Herrington
Top Company Interviews

Microsoft Corporation
Intel Corporation
Pfizer, Inc.
General Electric Company
Walmart Inc.
International Business Machines Corporation
Citigroup Inc.
Exxon Mobil Corporation
Bank of America Corporation
Dell Inc.
Verizon Communications Inc.
Alphabet Inc

Register for a Free Account to gain greater access to The Wall Street Transcript right now

CEO INTERVIEWS
Interview with the CEO: Pasithea Therapeutics Corp. (NASDAQ:KTTA)
Interview with the CEO: BetterLife Pharma Inc. (OTCMKTS:BETRF)
Interview with the CEO: Cansortium Inc. (OTCMKTS:CNTMF)
SECTOR ROUNDTABLES
Natural Gas Weighs Heavy On E&P Near-Term Prospects
Roundtable Forum:optimism Despite Uncertainty In For-profit Education
Roundtable Forum:a Shift In Focus To Natural Gas From Oil
MONEY MANAGER INTERVIEWS
AI Opportunities Expand to Industrial, Utilities and Energy Sectors
India Fund Manager Expects Discretionary Spending to Grow
Inefficiency in Ex-US Markets Creates Opportunity to Buy at a Discount
ANALYST INTERVIEWS
Five Companies Dominate in Psychedelics-Based Drug Development
Cidara’s Long-Acting Antiviral Drug Could Be a Game Changer
Spotting Potential in the High-Risk, High Reward Neuroscience Space
Since 1963
© The Wall Street Transcript 2016, 2024
Terms and Conditions
Privacy Policy